Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

A Phase 1 Study Of Sunitinib In Combination With S-1 And Cisplatin In Patients With Advanced Or Metastatic Gastric Cancer

To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of gastric cancer
• Chemonaive patients
• Adequate organ function

Exclusion Criteria:

• Patients who meet the contra-indications of S-1 and Cisplatin.
• Prior chemotherapy failure patients